Background: Genetic factors have a vital influence on the pathogenesis of hypertension. In this retrospective study, we aimed to evaluate the association of ADRB1 and CYP2D6 polymorphisms with antihypertensive effects and perform an analysis of their contribution to hypertension risk.
INTRODUCTION
E ssential hypertension (EH) is a polygenic disease caused by the combined effects of genetic and environmental factors. 1, 2 Despite much investigation, its etiology and pathogenesis are not completely understood. Recently, numerous studies have shown that genetic elements play a pivotal role in the pathogenesis of EH. 3, 4 β-blockers regulate the sympathetic response by blocking human β1-adrenergic receptor (ADRB1) and are important in the management of EH. ADRB1 is one of the members of a family of 7 transmembrane G-protein-coupled receptors. 5 In vitro studies have revealed that the patients with EH who carried the homozygous ADRB1 Arg389 variant showed a greater response to β-blocker stimulation than those who carried the Gly389 allele. 6, 7 Another hypertension-related gene, CYP2D6, may also be important for this; CYP2D6 polymorphism was reported to affect the metabolic rate of metoprolol in humans. 8, 9 However, whether ADRB1 polymorphisms are correlated with the morbid risk of hypertension remains controversial. 5 As noted, several studies have focused on either ADRB1 or CYP2D6, but no study of these genes has focused on evaluating the risk of hypertension onset and treatment for patients with hypertension. Here, we aimed to determine the association of ADRB1 and CYP2D6 polymorphisms with the risk of suffering from EH and the antihypertensive effect of the β-blocker metoprolol.
MATERIALS AND METHODS

Ethics Statement
This study was approved by the Ethics Committee of the First Hospital of Longyan, Fujian (2012002). All patients provided signed informed consent. All the clinical specimens analyzed in this work were collected as part of routine medical care.
Study Subjects
A total of 261 patients with EH who were hospitalized in the First Hospital of Longyan, Fujian and 261 healthy controls were enrolled from July 2012 to December 2015. The cases followed the diagnostic standards of hypertension set by World Health Organization/International Society of Hypertension (WHO/ISH) in February 1999. 10 We excluded patients with comorbidity owing to severe heart, liver or kidney disease, patients for whom administration of other drugs would affect metoprolol treatment and cases with incomplete clinical data or dropout.
For analysis of the unrelated controls, we excluded patients with acute or chronic diseases or a family history of the same as well as patients with abnormal findings in their blood, urine, stool, serum biochemistry, blood stream changes, chest X-ray, heart and abdomen ultrasound or electrocardiograph.
Specimen Collection
The following general clinical information was collected: gender, age, height, weight, systolic blood pressure (SBP), diastolic blood pressure (DBP), triglyceride (TG) levels, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), fasting blood glucose (FBG) and uric acid (UA) levels.
All the patients received treatment with metoprolol (25 mg twice a day) or metoprolol tartrate sustainedrelease tablets (40.5 mg once a day) for 12 weeks; blood pressure was measured once every 4 weeks. The treatment was considered to be effective if a decrease of ≥10 mm Hg in systolic blood pressure was found. Before the treatment, 2 mL of blood was collected in an EDTA-Na 2 anticoagulant tube from each patient and was sent to Yi Shan Medical Testing Center of Guangzhou for genotyping.
Definition
High FBG was defined as venous plasma FBG ≥ 6.1 mmol/L. Dyslipidemia was defined as high TC ≥ 5.18 mmol/L, high LDL-C ≥ 3.37 mmol/L, high TG ≥ 1.70 mmol/L and low HDL-C o 1.04 mmol/L. High UA was defined as fasting SUA levels on 2 different days were above 420 μmol/L (men) or 360 μmol/L (women) under normal state purine diet. Smoking status was defined as 1 pack a week for more than 6 months.
Genotyping and the xTAG Liquid Chip Technology
Peripheral blood DNA was extracted and then used to detect the genotypes ADRB1 and CYP2D6. The main steps involved in the xTAG liquid chip technology were as follows: (1) Multiplex PCR amplification (including the gene sequence of the mutation site) using the following primers: ADRB1 wild-type primer, 5′-CCGCAAGGC CTTCCAGG-3′; ADRB1 mutant primer, 5′-CGCA AGGCCTTCCAGC-3′; CYP2D6 wild-type primer, 5′ -GGGCTGCACGCTACC-3′; CYP2D6 mutant primer, 5′ -GGGCTGCACGCTACT-3′. (2) PCR product digestion by exonuclease enzyme I (EXO I) and shrimp alkaline phosphatase (SAP); excess primers and free nucleotides were removed. (3) Multiplex allele-specific primer extension/target specific primer extension was performed, with the right end of the primer connected to the specific sequence of the mutation site in the target gene, and the left end connected to a tag sequence. (4) The allelespecific primer extension reaction product was hybridized with a probe labeled with an anti-tag specific antibody wrapped in polystyrene microspheres. After hybridization, streptavidin-biotin (PE) was added to produce fluorescence; finally, data were obtained on Luminex 200 and analyzed to determine the genotype of each locus in the sample.
Statistical Analysis
All data were analyzed with SPSS 19.0 software and P o 0.05 was considered statistically significant. Data are displayed as mean ± standard deviation, median (quartiles) or percentage. Measurement data were compared between groups by the t test, Mann-Whitney U test or χ 2 test. Multivariate logistic regression and the generalized linear mixed model were used to assess hypertension-related risk factors. Two-factor repeated measures analysis of variance was used to evaluate the association of β-blocker antihypertensive efficacy with ADRB1 and CYP2D6 polymorphisms.
RESULTS
Patient Characteristics
The values obtained for age, BMI, SBP, DBP, TG, TC, LDL-C, FBG and UA were significantly higher in hypertensive patients than that in the controls (P o 0.05). However, no differences in gender composition or HDL-C (P 4 0.05, Table 1 ) were found. The ages of the hypertensive patients were mostly between 40 and 59 years. Patients with grade II hypertension accounted for 81.6%; cases with a disease course ≥1 year accounted for 92.7% of cases (Table 2) .
Frequency Distribution of ADRB1 and CYP2D6 Polymorphisms
Of the 261 EH patients studied, 46 (18%) were Arg/ Arg, 118 (45.2%) were Arg/Gly and 97 (37%) were Gly/ Gly ADRB1 genotypes. In the case of CYP2D6, 40 (15%) had wild-type *1/*1, 105 (40.2%) the *10/*10 homozygotes and 116 (44.4%) the *1/*10 heterozygotes. As shown in Table 3 , minor allele frequencies in the EH and control groups were 59.8% and 70.3% for the ADRB1 allele and 64.6% and 65.9% for the CYP2D6 allele, respectively. The genotype and allele distribution of ADRB1 were significantly different between the 2 groups (P o 0.05), but no significant differences were found for 236 THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES VOLUME 355 NUMBER 3 March 2018 CYP2D6 (P 4 0.05). The 2 single nucleotide polymorphisms (SNPs) fit the Hardy-Weinberg equilibrium for both groups (P 4 0.05).
Logistic Regression Analysis for Multivariate Factors of Hypertension
To determine the influence of genetic risk factors with respect to hypertension, we used a multivariate logistic regression model ( Table 4 ). The gene polymorphisms were classified into pairs: Arg/Arg þArg/Gly and Gly/Gly for Arg389Gly ADRB1 and *1/*1 þ *1/*10 and *10/*10 for CYP2D6. In this model, which merged common risk factors into confounding factors, the Gly/ Gly polymorphism of Arg389Gly ADRB1 emerged as an independent risk factor along with advanced age, high BMI, smoking, high TG and high FBG, while low HDL emerged as a protective factor of hypertension.
Association of Drug Efficacy With ADRB1 and CYP2D6 Polymorphisms
An analysis between ADRB1 and CYP2D6 genotypes and blood pressure changes occurring in patients during the 12 weeks of treatment was performed, confirming that the ADRB1 genotype was primarily responsible for the antihypertensive effect of metoprolol, which was significantly affected by various ADRB1 mutations (F ¼ 2.75, P ¼ 0.016). Interestingly, Tukey's post hoc test demonstrated that the antihypertensive effect of metoprolol in patients with a homozygous ADRB1 mutation was better than the effect of those with a heterozygous ADRB1 mutation (P ¼ 0.027). Data regarding the effects of the CYP2D6 polymorphism on the outcome of antihypertensive therapy were not statistically significant (data not shown).
DISCUSSION
EH is a systemic disease with increased arterial blood pressure as the main clinical manifestation. It is the most common cardiovascular disorder and a major risk factor for cardiovascular disease mortality.
1 EH has proven difficult to treat successfully owing to individual susceptibility. Genetic factors have a critical influence on the pathogenesis of hypertension. 3, 4 In this study, the frequencies of ADRB1 and CYP2D6 polymorphisms in an EH population were determined. We found that ADRB1 genotypes and the allele frequency distribution of hypertensive patients were significantly different compared to that in the controls (P o 0.05). In contrast, this analysis for CYP2D6 genotypes did not reveal significant differences, demonstrating that there is a relationship between the ADRB1 polymorphism and hypertension. Nevertheless, we could not determine whether CYP2D6 is associated with hypertension or not.
Many studies have demonstrated that the Arg allele is associated with hypertensive risk, while the Gly allele confers lower risk for hypertension. [5] [6] [7] [8] [9] [10] [11] However, the Gly/ Gly polymorphism in our study emerged as an independent risk factor (Gly/Gly versus Arg/Gly þ Arg/Arg: P = 0.027, Moreover, due to complex interactions and synergistic or antagonistic effects among genes, possible influence by SNPs of other genes near ADRB1 that affect the correlation between ADRB1 and EH pathogenesis cannot be ruled out. Additionally, though Arg389 β1AR is hyperfunctional at the molecular and signaling levels and quite likely to be hyperfunctional at the physiological level, the native receptors uniformly supported the hyperfunctional role of Gly389, but not of Arg389. 11, 12 Moreover, the Arg389 β 1 AR hyperfunctional features may only become apparent when contraction force is severely impaired. 12 Therefore, whether the Arg389Gly variation influences hypertension risk remains an open question. This is also a possible reason why our results differed from those of others.
Besides genetic factors, there are various confounding factors such as age, dyslipidemia, obesity, elevated fasting glucose, social circumstances as well as lifestyle and region, which are regarded as effective influence factors for the development of hypertension. 13, 14 Our results also showed that high FBG, smoking, high TG, advanced age and high BMI were independent risk factors along with the Gly/Gly polymorphism, suggesting that hypertension incidence is associated with age and diet, corroborating a finding reported by Wei et al. 13 High FBG, smoking, and high TG were more likely to increase the risk of onset hypertension than the Gly/Gly polymorphism of ADRB1. Therefore, it is possible that environmental confounders might function in concert to increase the probability of an individual developing EH.
With regards to drug response, these cardiovascular risk factors also affected the treatment of patients with hypertension. 15 Currently, the proportion of hypertensive patients receiving inappropriate treatment is as high as 60%. This might be owing to individual differences caused by genetic factors. 16 In this study, the ADRB1 polymorphism was found to have greater impact on the antihypertensive effect of metoprolol than the CYP2D6 polymorphism (F ¼ 2.75, P ¼ 0.016), in agreement with previous studies. [17] [18] [19] Meanwhile, the Gly/Gly polymorphism in Arg389Gly ADRB1 was particularly significant for the antihypertensive effect of metoprolol. Related studies demonstrated that patients carrying the Gly389 allele respond better to a reduction in systolic/diastolic blood pressure, with increased risk of primary hypertension. 5, 20 Although CYP2D6 genetic variation clearly impacts metabolism of several crucial drugs used in clinical settings, causing vast differences in responses to drugs among patients, 21 the effects of CYP2D6 polymorphism on responses to metoprolol were not statistically significant in our study. This may be attributed to the stronger effects of ADRB1 polymorphism on the outcome of antihypertensive therapy with metoprolol rather than CYP2D6. Thus, ADRB1 polymorphism is a major factor affecting the antihypertensive effect of metoprolol and personalized therapy can be performed according to patient genotype, which will effectively improve hypertension therapy. Our data demonstrate that genetic factors such as ADRB1 Gly/Gly homozygote rank second only to high FBG, smoking and high TG as the main independent risk factors for EH onset. Patients with ADRB1 polymorphism, especially with its homozygous form, show better response to metoprolol compared with those harboring the heterozygous variant. However, the results should be interpreted with caution for the following limitations: First, the sample size in our study is small; a large enough sample size to detect genetic and environmental effects for hypertension is needed. Second, we only analyzed the association of ADRB1 and CYP2D6 polymorphism with EH and drug efficacy related to target genes, such as the G-protein gene, was not investigated. Third, only the results for the recessive genetic model were positive and no relative evidence has yet been found in vivo or in vitro regarding what genetic modes of inheritance this SNP follows. Thus, welldesigned large-scale cross-sectional or longitudinal studies examining genotype-phenotype relationships and gene-gene and gene-environment interactions should be implemented to comprehensively address these results. Overall, our study highlights the need for a patient-centered treatment approach in EH; the best strategy for the prevention of EH must emphasize the importance of good dietary habits and lifestyle.
